Phase III KEYNOTE-355 study of pembrolizumab (pembro) vs placebo (pbo) plus chemotherapy (chemo) for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC): Results for patients (Pts) enrolled in Asia

被引：3

作者：

Yusof, M. Md ^{[1
]}

Cescon, D. W. ^{[2
]}

Rugo, H. S. ^{[3
]}

Im, S-A. ^{[4
]}

Gallardo, C. ^{[5
]}

Lipatov, O. ^{[6
]}

Barrios, C. H. ^{[7
]}

Holgado, E. ^{[8
,9
,10
]}

Iwata, H. ^{[11
]}

Masuda, N. ^{[12
]}

Gokmen, E. ^{[13
]}

Loi, S. ^{[14
]}

Guo, Z. ^{[15
]}

Jensen, E. ^{[15
]}

Aktan, G. ^{[16
]}

Karantza, V. ^{[16
]}

Schmid, P. ^{[17
]}

Cortes, J. ^{[18
,19
,20
,21
]}

机构：

[1] Pantai Hosp, Dept Oncol, Kuala Lumpur, Malaysia

[2] Univ Toronto, Princess Margaret Canc Ctr, Toronto, ON, Canada

[3] Univ Calif San Francisco, Dept Hematol Oncol, Ctr Comprehens Canc, San Francisco, CA 94143 USA

[4] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea

[5] Arturo Lopez Perez Fdn, Inst Oncol, Santiago, Chile

[6] Republican Clin Oncol Dispensary, Dept Oncol, Republic Bashkortostan, Russia

[7] Pontificia Univ Catolica Rio Grande do Sul, HSL, Ctr Pesquisa Oncol, Dept Med, Porto Alegre, RS, Brazil

[8] IOB Inst Oncol, Quironsalud Grp, Breast Canc Program, Madrid, Spain

[9] IOB Inst Oncol, Quironsalud Grp, Breast Canc Program, Barcelona, Spain

[10] Ramon & Cajal Univ Hosp, Madrid, Spain

[11] Aichi Canc Ctr Hosp, Dept Breast Oncol, Nagoya, Aichi, Japan

[12] Osaka Natl Hosp, Natl Hosp Org, Dept Surg, Breast Oncol, Osaka, Japan

[13] Ege Univ, Dept Med Oncol, Med Fac, Izmir, Turkey

[14] Peter MacCallum Canc Inst, Dept Res & Canc Med, Melbourne, Vic, Australia

[15] Merck & Co Inc, Biostat, Kenilworth, NJ USA

[16] Merck & Co Inc, Oncol, Kenilworth, NJ USA

[17] Barts Canc Inst, Centre Expt Canc Med, London, England

[18] IOB Inst Oncol, Breast Canc Program, Quironsalud Grp, Madrid, Spain

[19] IOB Inst Oncol, Breast Canc Program, Quironsalud Grp, Barcelona, Spain

[20] Vall dHebron Inst Oncol, Madrid, Spain

[21] Vall dHebron Inst Oncol, Barcelona, Spain

来源：

ANNALS OF ONCOLOGY | 2020年 / 31卷

关键词：

D O I：

10.1016/j.annonc.2020.10.063

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

430

引用

页码：S1257 / S1257

页数：1

共 50 条

[21] KEYNOTE-355: Final results from a randomized, double-blind phase III study of first-line pembrolizumab plus chemotherapy vs placebo plus chemotherapy for metastatic TNBC
Cortes, J.
Cescon, D. W.
Rugo, H. S.
Im, S-A.
Yusof, M. Md
Gallardo, C.
Lipatov, O.
Barrios, C. H.
Perez-Garcia, J.
Iwata, H.
Masuda, N.
Otero, M. Torregroza
Gokmen, E.
Loi, S.
Guo, Z.
Zhou, X.
Karantza, V.
Pan, W.
Schmid, P.
ANNALS OF ONCOLOGY, 2021, 32 : S1289 - S1290
[22] Pembrolizumab (pembro) plus chemotherapy (chemo) as neoadjuvant treatment for triple negative breast cancer (TNBC): Preliminary results from KEYNOTE-173
Schmid, Peter
Park, Yeon Hee
Munoz-Couselo, Eva
Kim, Sung-Bae
Sohn, Joohyuk
Im, Seock-Ah
Holgado, Esther
Wang, Yang
Dang, Thao
Aktan, Gursel
Cortes, Javier
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[23] TOPACIO/Keynote-162: Niraparib plus pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC), a phase 2 trial
Vinayak, Shaveta
Tolaney, Sara M.
Schwartzberg, Lee Steven
Mita, Monica M.
McCann, Georgia Anne-Lee
Tan, Antoinette R.
Hendrickson, Andrea Elisabeth Wahner
Forero-Torres, Andres
Anders, Carey K.
Wulf, Gerburg M.
Dillon, Patrick M.
Lynce, Filipa
Zarwan, Corrine
Erban, John Kalil
Dezube, Bruce Jeffrey
Zhou, Yinghui
Buerstatte, Nathan
Arora, Sujata
Achour, Haroun
Telli, Melinda L.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[24] KEYLYNK-009: A phase 2/3, open-label, randomized study of pembrolizumab plus olaparib vs pembrolizumab plus chemotherapy after induction with first-line pembrolizumab plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)
Rugo, Hope
Llombart-Cussac, Antonio
Andre, Fabrice
Robson, Mark E.
Saji, Shigehira
Harbeck, Nadia
Schmid, Peter
Cescon, David
Ahn, Jin Seok
Nanda, Rita
Fan, Li
Mejia, Jaime Alberto
Karantza, Vassiliki
Bardia, Aditya
CANCER RESEARCH, 2021, 81 (04)
[25] Phase III KEYNOTE-585 study of chemotherapy (Chemo) plus pembrolizumab (Pembro) vs chemo plus placebo as neoadjuvant/adjuvant treatment for patients (Pts) with gastric or gastroesophageal junction (G/GEJ) cancer
Bang, Y-J.
Van Cutsem, E.
Fuchs, C. S.
Ohtsu, A.
Tabernero, J.
Ilson, D. H.
Hyung, W. J.
Strong, V. E.
Goetze, T. O.
Yoshikawa, T.
Tang, L. H.
Hwang, P. M. T.
Adelberg, D.
Shitara, K.
ANNALS OF ONCOLOGY, 2018, 29 : 268 - 268
[26] KEYLYNK-009: A phase II/III, open-label, randomized study of pembrolizumab (pembro) plus olaparib (ola) vs pembro plus chemotherapy after induction with first-line (1L) pembro + chemo in patients (pts) with locally recurrent inoperable or metastatic TNBC
Saji, S.
Cussac, A. Llombart
Andre, F.
Robson, M. E.
Harbeck, N.
Schmid, P.
Cescon, D. W.
Ahn, J. S.
Nanda, R.
Fan, L.
Mejia, J. A.
Karantza, V.
Bardia, A.
Rugo, H. S.
ANNALS OF ONCOLOGY, 2020, 31 : S1268 - S1268
[27] KEYNOTE-119: Phase III study of pembrolizumab (pembro) versus single-agent chemotherapy (chemo) for metastatic triple negative breast cancer (mTNBC)
Cortes, J.
Lipatov, O.
Im, S-A.
Goncalves, A.
Lee, K. S.
Schmid, P.
Tamura, K.
Testa, L.
Witzel, I.
Ohtani, S.
Zambelli, S.
Harbeck, N.
Andre, F.
Dent, R.
Zhou, X.
Karantza, V.
Mejia, J. A.
Winer, E. P.
ANNALS OF ONCOLOGY, 2019, 30 : 859 - +
[28] A phase II/III, open-label, randomized trial of pembrolizumab plus olaparib vs. pembrolizumab plus chemotherapy after induction with pembrolizumab plus chemotherapy in locally recurrent inoperable or metastatic triple-negative breast cancer: KEYLYNK-009
Rugo, H. S.
Llombart Cussac, A.
Andre, F.
Robson, M.
Saji, S.
Harbeck, N.
Schmid, P.
Cescon, D. W.
Ahn, J. Seok
Nanda, R.
Fan, L.
Mejia, J.
Karantza, V.
Bardia, A.
ANNALS OF ONCOLOGY, 2020, 31 : S392 - S392
[29] Phase III study of neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for early-stage triple-negative breast cancer (TNBC): KEYNOTE-522 Korean subgroup analysis
Park, Y. H.
Im, S-A.
Ahn, J-H.
Kim, M. H.
Cortes, J.
Dent, R. A.
Pusztai, L.
McArthur, H. L.
Kummel, S.
Denkert, C.
O'Shaughnessy, J.
Mouret-Reynier, M-A.
Ferreira, M. I. R.
Cortes, M. Gion
Boileau, J-F.
Hui, R.
Zhu, Y.
Pan, W.
Karantza, V. V.
Schmid, P.
ANNALS OF ONCOLOGY, 2023, 34 : S1467 - S1468
[30] Safety evaluation from the KEYNOTE-522 study of neoadjuvant pembrolizumab (or placebo) plus chemotherapy followed by adjuvant pembrolizumab (or placebo) in patients with early triple-negative breast cancer (TNBC)
Cortes, Javier
Dent, Rebecca
Pusztai, Lajos
McArthur, Heather
Kuemmel, Sherko
Denkert, Carsten
Park, Yeon Hee
Hui, Rina
Takahashi, Masato
Barrios, Carlos
Zhu, Yalin
Zhang, Xiaoli
Pan, Wilbur
Karantza, Vassiliki
O'Shaughnessy, Joyce
Schmid, Peter
CANCER RESEARCH, 2024, 84 (09)

← 1 2 3 4 5 →